Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy
Authors:
- Nicoletta ColomboNCNicoletta Colombo
- Martin GoreMGMartin Gore
- 1 November 2007
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 64 (2) , 129-138
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trialAnnals of Oncology, 2006
- Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian CancerOncology, 2005
- Treatment goals in ovarian cancerInternational Journal of Gynecological Cancer, 2005
- Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian CancerThe Oncologist, 2005
- Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistanceInternational Journal of Gynecological Cancer, 2005
- Recurrent Ovarian CancerClinical Cancer Research, 2004
- Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecologic Oncology, 2004
- Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial DesignJournal of Clinical Oncology, 2004
- Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.Journal of Clinical Investigation, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990